Current Size: 100%
CaPPE - Cancer Pharmacoepidemiology & Pharmacoeconomics

CaPPE is a collaboration between the National Cancer Registry, the Department of Pharmacology & Therapeutics, Trinity College Dublin and the National Centre for Pharmacoeconomics. The focus of the collaboration is research in the areas of cancer pharmacoepidemiology and pharmacoeconomics. Pharmacoepidemiology research involves the investigation – at the population-level – of the effects of medications on cancer. Pharmacoeconomics assesses the economic impact of medications and drugs in cancer.
Cancer pharmacoepidemiology research in Ireland is made possible by the bringing together - by the National Cancer Registry - of individual records for cancer and prescribed medications, held by the Primary Care Reimbursement Service. The collaboration has been funded by several project and programme grants from the Health Research Board and PhD studentships from the Irish Cancer Society. Current projects include:
- Adherence to aromatase inhibitors (hormonal therapy) in women with breast cancer, and how this affects outcome;
- Development of a theory-based intervention to enhance adherence to hormonal therapy in women with early-stage breast cancer;
- Associations between beta-blockers and outcomes in breast and other cancers;
- Impact of metformin and other anti-diabetic drugs in colorectal cancer;
- Associations between digoxin and prostate cancer outcomes;
- Associations between non-steroidal anti-inflammatory drugs and breast, prostate, and ovarian cancers
- How do ovarian cancer patients with and without medical cards differ?
- National Cancer Research Institute (NCRI) Cancer Conference 2015
- Does taking aspirin reduce the risk of breast cancer spreading?
- National Cancer Registry supports Daffodil Day 2014
- Photos of ICE Awards Conference 2014
- Use of the anti-diabetic drug metformin may be associated with lower chances of being diagnosed with disseminated colorectal cancer
- Pre-diagnostic use of aspirin may be associated with lower mortality in men with prostate cancer
- Cancer Pharmacoepidemiology Symposium - Presentations now available
- Can demographic, clinical and treatment-related factors available at hormonal therapy initiation predict non-persistence in women with stage I-III breast cancer?
- De-novo post-diagnosis aspirin use and mortality in women with stage I-III breast cancer
- Recent prediagnostic aspirin use, lymph node involvement, and 5-year mortality in women with stage I-III breast cancer: A nationwide population-based cohort study
- A cohort study investigating aspirin use and survival in men with prostate cancer
- Metformin exposure and disseminated disease in patients with colorectal cancer
- A cohort study of digoxin exposure and mortality in men with prostate cancer
- A cohort study of metformin exposure and survival in patients with stage I-III colorectal cancer
- Beta-adrenergic blocking drugs in breast cancer: a perspective review
- Beta-blockers and breast cancer mortality: a population-based study
- A nested case-control study of adjuvant hormonal therapy persistence and compliance, and early breast cancer recurrence in women with stage I-III breast cancer